ArticleInternational journal of molecular medicine2015
MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1.
Article in International journal of molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- MiR-218 Exhibits Anti-Leukemia Effects by Targeting CTNND2 in Primary Acute Erythroid Leukemia HEL Cells.Cell biochemistry and biophysics · 2025Article
- Development and validation of a novel signature to predict the survival and affect the immune microenvironment of esophageal squamous cell carcinoma: epigenetic-related genes.Frontiers in immunology · 2025Article
- MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma.World journal of gastroenterology · 2024Review
- Article
- Roles of microRNAs in tumorigenesis and metastasis of esophageal squamous cell carcinoma.World journal of clinical oncology · 2021Review
- Role of miR-218-GREM1 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma: An in vivo and vitro study based on microarray data.Journal of cellular and molecular medicine · 2020Article
- miR-218 suppresses the proliferation of osteosarcoma through downregulation of E2F2.Oncology letters · 2019Article
- Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1.Oncology reports · 2017Article
- Propofol Suppresses Esophageal Squamous Cell Carcinoma Cell Migration and Invasion by Down-Regulation of Sex-Determining Region Y-box 4 (SOX4).Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Lycopene inhibits the cell proliferation and invasion of human head and neck squamous cell carcinoma.Molecular medicine reports · 2016Article
- Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.Oncology reports · 2016Article
- The role of microRNA in esophageal squamous cell carcinoma.Journal of gastroenterology · 2016Review
- Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer.Oncotarget · 2016Article
- MiR-218 increases sensitivity to cisplatin in esophageal cancer cells via targeting survivin expression.Open medicine (Warsaw, Poland) · 2016Article
- MiR-27a-3p promotes esophageal cancer cell proliferation via F-box and WD repeat domain-containing 7 (FBXW7) suppression.International journal of clinical and experimental medicine · 2015Article
- miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin7.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs or miRs) play a pivotal role in esophageal carcinogenesis either as oncogenes or as tumor suppressor genes. In the present study, we found that the expression level of miR-218 was significantly reduced in esophageal squamous cell carcinoma (ESCC) tissues and ESCC cell lines. Moreover, its expression was found to correlate with the clinicopathological stage of ESCC; miR-218 expression was lower in the stage III tissue samples than in the stage I and II tissue samples. Furthermore, the decreased expression of miR-218 was found to be associated with an enhanced ESCC cell proliferation and metastasis. Western blot analysis and luciferase reporter assay revealed that miR-218 decreased BMI1 expression by binding to the putative binding sites in its 3'-untranslated region (3'-UTR). The BMI1 mRNA expression levels were markedly increased and negatively correlated with the miR-218 expression level in the ESCC tissues. Functional analyses revealed that the restoration of miR-218 expression inhibited ESCC cell proliferation, migration and invasion and promoted apoptosis. The knockdown of BMI1 by siRNA showed the same phenocopy as the effect of miR-218 on ESCC cells, indicating that BMI1 was a major target of miR-218. In the present study, our findings confirm miR-218 as a tumor suppressor and identify BMI1 as a novel target of miR-218 in ESCC. Therefore, miR-218 may prove to be a useful biomarker for monitoring the initiation and development of ESCC, and may thus be an effective therapeutic target in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.